Results 51 to 60 of about 225,446 (206)

Graves' ophthalmopathy: natural history and treatment outcomes

, 2001
The pathogenesis of Graves' ophthalmopathy has not been yet clarified, and from a therapeutic standpoint Graves' ophthalmopathy remains an enigma.
Bürgi, U, Noth, D, Diem, P, Gebauer, M, Müller, B   +4 more
core   +1 more source

Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar, Pedro Lança Gomes, Gaurav Jategaonkar, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source

Clinical and Radiological Findings in Patients with Newly Diagnosed Graves’ Ophthalmopathy

International Journal of Endocrinology, 2021
Background. Graves’ ophthalmopathy is the most common extrathyroidal manifestation of Graves’ disease. The objective of this study was to investigate the clinical ophthalmological and MRI findings in newly diagnosed Graves’ ophthalmopathy. Methods.
Yakup Cevik, Hande Taylan Sekeroglu, Burce Ozgen, Kadriye Erkan Turan, Ali Sefik Sanac   +4 more
doaj   +1 more source

Research progress on the pathogenesis of Graves’ ophthalmopathy: Based on immunity, noncoding RNA and exosomes

Frontiers in Immunology, 2022
Graves’ ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy, is a common potentially vision-threatening organ-specific autoimmune disease and the most common extrathyroidal manifestation of Graves’ disease.
Jingyi Zheng, Jingyi Zheng, Honghong Duan, Sufang You, Sufang You, Bo Liang, Yuping Chen, Yuping Chen, Huibin Huang   +8 more
doaj   +1 more source

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source

A Case of Euthyroid Graves’ Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody

Case Reports in Endocrinology, 2018
We report of a case of Graves’ ophthalmopathy presented solely with symptoms of the eyes with normal thyroid function tests and negative immunoreactive TSH receptor autoantibody.
Asami Hotta, Tomohiro Tanaka, Haruka Kato, Shota Kakoi, Yuki Shimizu, Chie Hasegawa, Akiko Hayakawa, Satoshi Yasuda, Kento Ogawa, Shunsuke Ito, Hideomi Ohguchi, Takashi Yagi, Hiroyuki Koyama, Mihoko Kawamura, Kazuhiko Sugitani, Yuichiro Ogura, Takashi Joh, Kenro Imaeda   +17 more
doaj   +1 more source

Immunological Aspects of Graves’ Ophthalmopathy [PDF]

BioMed Research International, 2019
The body’s autoimmune process is involved in the development of Graves’ disease (GD), which is manifested by an overactive thyroid gland. In some patients, autoreactive inflammatory reactions contribute to the development of symptoms such as thyroid ophthalmopathy, and the subsequent signs and symptoms are derived from the expansion of orbital adipose ...
Łacheta, Dominika, Piotr Stefan Miśkiewicz, Alicja Głuszko, Grażyna Joanna Nowicka, Marta Katarzyna Struga, Kantor, Ireneusz, Poślednik, Krzysztof, Mirza, Shafaq, Mirosław Jerzy Szczepański   +8 more
openaire   +2 more sources

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

Advanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

Hypothyroid Graves’ Ophthalmopathy: Report of Two Cases

Endocrinology Research and Practice, 2007
Graves’ disease is an autoimmune disorder of the thyroid gland. Ophthalmopathy is the most common peripheral manifestation of Graves’ disease. It is a very rare condition that a Graves’ patient presents with spontaneous hypothyroidism.
Barış Akıncı, Tevfik Demir, Abdurrahman Çömlekçi   +2 more
doaj   +2 more sources

A Pruritic Predicament: An Unusual Presentation of Graves’ Disease Complicated by Pregnancy

Case Reports in Medicine, Volume 2026, Issue 1, 2026.
Pruritus is a known but uncommon symptom of hyperthyroidism that can be misinterpreted or overlooked in a patient presentation. This is a case report of a 40‐year‐old female who presents with a 3‐month history of severe, worsening pruritus. Further history demonstrated potential signs of hyperthyroidism, and laboratory values demonstrated low TSH ...
Rob Lawless, Evan Smith, Camryn Slone, Thaddeus Salmon, Semonti Nandi   +4 more
wiley   +1 more source